Anticancer Therapies – News and Features

A study reveals that the way cancer cells die after radiotherapy depends on DNA repair methods. By blocking specific repair pathways, scientists can prompt immune responses against cancer cells.

A study finds that a sensitive test detecting circulating tumour DNA (ctDNA) in early-stage lung cancer can predict relapse risk and survival. This approach could help doctors personalize treatment and improve patient outcomes.

A new look at cancer cells: Würzburg researchers show how therapeutic antibodies work – thanks to an innovative method of super-resolution microscopy.

A collaborative team has created inhalable mucoadhesive protein nanoparticles inspired by mussel adhesive properties. These biocompatible particles enable targeted delivery of anticancer drugs to the lung cancer microenvironment.

A new drug currently in trials for ovarian and bile duct cancer may also treat hormone therapy-resistant prostate cancer.

The adaptive immune system is highly complex and specific. In this article we focus on T cells, and discuss their development, their different functions, and what happens when they don't function correctly.

Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors.

UC researchers reveal that miR-205 regulates MED1 and HER3, proteins driving breast cancer treatment resistance. Boosting miR-205 levels could block MED1 production and activity, enhancing therapy outcomes.

Researchers have revealed a previously unknown mechanism that triggers an inflammatory immune response in cells when their DNA is damaged.

Research into cancer-associated fibroblasts could make cancer immunotherapy more effective.